Powel Brown, MD
Enriched profileProfessor, Department of Clinical Prevention, MD Anderson Cancer Center (per AACR profile listing; ORCID lists Professor at MD Anderson as past) · University of Texas MD Anderson Cancer Center
Powel Brown is Professor, Department of Clinical Prevention, MD Anderson Cancer Center (per AACR profile listing; ORCID lists Professor at MD Anderson as past) at University of Texas MD Anderson Cancer Center. OpenAlex indexes 791 publications with 15,560 citations (h-index 66); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the FindMyKOL directory.
Data verified 23 Oct 2026
Overview
Updated 25 Oct 2026
Powel Brown, PHD, is Professor, Department of Clinical Prevention, MD Anderson Cancer Center (per AACR profile listing at University of Texas MD Anderson Cancer Center. The public record shows 791 publications with 15,560 citations (h-index 66), centered on Breast Cancer Treatment Studies, Estrogen and related hormone effects, Breast Lesions and Carcinomas. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 1 companies, 12 NIH-funded awards (1999–2023).
- Most recent indexed publication: 2026 · Cancer prevention research (Philadelphia, Pa.)
- Top research focus: Breast Cancer Treatment Studies
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 169.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Sponsor: National Cancer Institute (NCI)
- Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Sponsor: National Cancer Institute (NCI)
- Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 25 Oct 2026
1 company reported payments to CMS in program years 2021–2021. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20211 payment
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Anastrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 25 Oct 2026
12 NIH research awards on record, funded 1999–2023 per NIH RePORTER. The latest:
- OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
University of Tx Md Anderson Can Ctr
FY2023$183,238261201200034I - PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers-- Targeting the PARP Pathway for the Prevention of Breast Cancer
University of Tx Md Anderson Can Ctr
FY2022$1,121,09075N91019D00021
Congress activity
Updated 25 Oct 2026
78 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 963: Preclinical testing of A2B adenosine receptor inhibitor PSB1115 for pancreatic cancer immunoprevention
AACR Annual Meeting
AACR2026Co-author - Abstract 6332: Targeting PARP for the prevention of BRCA1-deficient triple-negative breast cancers
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 25 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer.
Cancer prevention research (Philadelphia, Pa.)
Article2026 - Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.
Nature medicine
Clinical Trial2026 - Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer.
Molecular cancer therapeutics
Article2026 - Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia.
Cancer prevention research (Philadelphia, Pa.)
Article2024 - IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
Clinical cancer research
Article2024
Most-cited works
by citation count (OpenAlex)- 01Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerArticle1,396 citations2014
- 02
- 03
- 04ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsArticle519 citations2015
- 05Prevention and early detection of prostate cancerArticle496 citations2014
Network
Updated 25 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD (New York University), per secondary profile summary
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.viictr.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →prevention.cancer.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Farhad Ravandi-Kashani, MD
University of Texas MD Anderson Cancer Center
Anita Deswal, MD
University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope